Feasibility research of combined assay with serum tumor marker and low dose CT on the early diagnosis of lung cancer

Purpose: To explore the feasibility of combined assay with serum tumor marker and low dose CT on the early diagnosis of lung cancer. Method: 60 newly diagnosed lung cancer patients (lung cancer group), 60 benign lung disease patients (benign group) and 60 healthy subjects (health group) were included. All participants were diagnosed by serum tumor marker and low dose CT. Result: There are few notable differences in the imaging situation and image quality through CT examination of lung cancer with different volume, P>0.05. Radiation dosage of the ultra-low dose group is obviously lower than that of the other two groups, P<0.05. The level of NSE (Neuron specific enolase), CEA (carcinoembryonic antigen), PTN (Human Pleiotrophin) and Cyfra21-1 among the lung cancer group is significantly higher than that among the benign group and the health group. With the separate detection of NSE, CEA, PTN and Cyfra21-1, the combined measurement of tumor markers and serum tumor marker measurements with low CT dose, positive rate of the lung cancer group detected by the result is considerably higher than that of the benign group, P<0.05. Conclusion: The combined assay with serum tumor marker and low dose CT proves to be highly feasible on the early diagnosis of lung.